Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Erlotinib With or Without SNDX-275 (Entinostat) in the Treatment of Patients With Advanced NSCLC

ClinicalTrials.gov ID: NCT00602030

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00602030. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 17, 2026, 3:38 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Placebo-controlled, Double-blind, Multicenter Phase 2 Study With a Lead in Phase of Erlotinib With or Without SNDX-275 in Patients With NSCLC After Failure In Up to Two Prior Chemotherapeutic Regimens for Advanced Disease

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with erlotinib in the treatment of Advanced Non-Small Cell Lung Cancer (NSCLC).

Study identification

NCT ID
NCT00602030
Recruitment status
Completed
Study type
Interventional
Phase
Phase 1, Phase 2
Lead sponsor
Syndax Pharmaceuticals
Industry
Enrollment
141 participants

Conditions and interventions

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 8, 2008 (Actual)
Primary completion
Feb 4, 2010 (Actual)
Completion
Feb 1, 2012 (Actual)
Last update posted
Aug 22, 2022

2008 – 2012

United States locations

U.S. sites
30
U.S. states
13
U.S. cities
29
Facility City State ZIP Site status
HOPE (Hematology Oncology Physicians & Extenders) Tucson Arizona — —
Rocky Mountain Cancer Center Denver Colorado — —
Advanced Medical Specialties Miami Florida — —
Ocala Oncology Center Ocala Florida — —
Cancer Centers of Florida Ocoee Florida — —
Hematology Oncology Associates of Illinois Chicago Illinois — —
Central Indiana Cancer Centers Indianapolis Indiana — —
Kansas City Cancer Centers Overland Park Kansas — —
Alliance Hematology Oncology Westminster Maryland — —
St Joseph Oncology Saint Joseph Missouri — —
The Center for Cancer Care & Research St Louis Missouri — —
Mahonig Valley Hematology Oncology Associates Boardman Ohio — —
Dayton Oncology & Hematology Kettering Ohio — —
Oncology Associates of Oregon Eugene Oregon — —
Texas Oncology Amarillo Texas — —
Texas Oncology Austin Texas — —
Texas Oncology Bedford Texas — —
Texas Oncology, Sammons Cancer Center Dallas Texas — —
Texas Oncology Dallas Texas — —
Texas Oncology Fort Worth Texas — —
Texas Oncology Garland Texas — —
Texas Oncology Longview Texas — —
Texas Oncology Midland Texas — —
Texas Oncology Odessa Texas — —
Texas Oncology Tyler Texas — —
Fairfax Northern Virginia Hematology-Oncology Fairfax Virginia — —
Virginia Oncology Associates Norfolk Virginia — —
Highline Medical Oncology Burien Washington — —
Cancer Care Northwest Spokane Washington — —
Yakima Valley Memorial Hospital/North Star Lodge Yakima Washington — —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00602030, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Aug 22, 2022 · Synced Nov 17, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.